US and Europe Cell and Gene Therapy Manufacturing Services Market Forecast to 2030 - Regional Analysis by Type [Cell Therapy (Autologous and Allogenic) and Gene Therapy (Viral Vectors and Non-Viral Vectors)], Indication (Cancer, Orthopedics, and Others), Application (Clinical Manufacturing and Commercial Manufacturing), and End User [Pharmaceutical and Biotechnology Companies and Contract Research Organization (CROs)], and Country
The US and Europe cell and gene therapy manufacturing services market was valued at US$ 4,773.5 million in 2022 and is projected to reach US$ 16,869.1 million by 2030; it is estimated to register a CAGR of 17.1% from 2022 to 2030.
An increase in number of approvals of cell and gene therapies and increasing popularity of outsourcing cell and gene therapy manufacturing services are among the major contributing factors influencing the growth of US and Europe cell and gene therapy manufacturing services market size. However, high initial cost of cell and gene therapy manufacturing services hinders the growth of the US and Europe cell and gene therapy manufacturing services market.
Cell and gene therapy (CGT) programs are rapidly advancing from research & development to clinical trials and commercial approval. Establishing a robust, repeatable, and sustainable process help to accelerate the development, avoiding manufacturing transfer-related delays. Additionally, cell and gene therapy comprises the next generation of life-enhancing and curative therapies. With therapies experiencing new approvals, the demand for skilled professionals in cell and gene therapy manufacturing services will rise.
Increasing Popularity of Outsourcing Cell and Gene Therapy Manufacturing
Cell and gene therapy manufacturing is a complex process, which makes the proper execution and overseeing of the operation crucial. Cell and gene therapy manufacturers have a limited number of qualified personnel who know biological and process engineering. Moreover, for experienced teams, managing the attempts to reach the first clinical trial using a manual, and open manufacturing method and then building a more commercially suitable process can be tricky. Therefore, these enterprises choose to work with contract development and manufacturing organizations (CDMOs) to accelerate their clinical studies and commercialization process. CDMOs provide product development, manufacturing, clinical trial support, and commercialization services to cell and gene therapy companies on a contract basis. Partnering with a CDMO enables scalability, speed to market, access to technical expertise without overhead costs, and cost efficiencies for cell and gene therapy manufacturers.
In January 2020, Deerfield Management Company and The Discovery Labs of MLP Ventures established the Center for Breakthrough Medicines in Pennsylvania, US. This new CDMO facility would occupy more than 40% of the campus created by The Discovery Labs. In that space, the CDMO would install 10 plasmid suites; 20 viral vector suites; 36 universal cell processing suites; and 20 current good manufacturing practice (cGMP) testing, process development, and cell banking suites. Deerfield Management Company and The Discovery Labs have invested US$ 1.1 billion to raise a technologically developed facility to support the manufacturing of cell and gene therapies. Further, in March 2020, Fujifilm Cellular Dynamics (FCDI) invested US$ 21 million in the cGMP-compliant production facility, which would be used for manufacturing FCDI’s pipeline of regenerative medicine therapies using induced pluripotent stem cells (iPSCs) and to provide CDMO services for production of iPSCs and iPSC-derived differentiated cells. In April 2022, ThermoGenesis established a CDMO facility in California, US to provide CDMO services to cell and gene therapy manufacturers, using its expertise in T-cell receptor (TCR), chimeric antigen receptor-T cell (CAR-T cell), tumor-infiltrating leukocyte (TIL), iPSC, natural killer cell (NK), and mesenchymal stem cell (MSC) manufacturing.
Outsourcing cell and gene therapy manufacturing to CDMOs proves cost-effective for manufacturers. Moreover, they gain access to the technologically advanced infrastructure and expertise of CDMOs. CDMOs employ proper, mapped processes for manufacturing cell and gene therapies. Thus, the increasing preference for outsourcing growing cell and gene therapy manufacturing to CDMOs fuels the US and Europe cell and gene therapy manufacturing services market growth.
Segmental Analysis
End User-Based Insights
Based on end user, the market is segmented into pharmaceutical and biotechnology companies and contract research organizations (CROs). The pharmaceutical and biotechnology companies segment held a larger share of the market in 2022 and the same segment is anticipated to register a higher CAGR in the market during the forecast period. Major US-based pharmaceutical and biotechnology companies committed to offering CGTs intended to treat acute and rare conditions, which are unresponsive to traditional approaches, include ElevateBio and Discovery Labs. These companies are focused on creating a completely new branch of pharmaceutical contract development and manufacturing organizations (CDMOs). They would compete with one another and with a handful of giant services firms by investing in CGTs. The aforementioned factors will be responsible for influential segmental growth thereby dominating the US and Europe cell and gene therapy manufacturing services market growth during 2022-2030.
Indication Insights
Based on indication, the US and Europe cell and gene therapy manufacturing services market is divided into cancer, orthopedics, and others. The cancer segment held the largest share of the market in 2022 and same segment is expected to grow at the highest CAGR during the forecast period.
Type Insights
Based on type, the cell and gene therapy manufacturing services market is segmented cell therapy and gene therapy. Cell therapy is segmented as autologous and allogenic. Further, gene therapy is bifurcated into viral vector and non-viral vector. Cell therapy helps treat disorders and diseases by restoring or changing certain groups of cells or providing cells to carry therapy through the body. Cell therapy forms or modifies cells outside the body before introducing into the patient. The cells may derive from the patient (autologous cells) or a donor (allogeneic cells). The growth of the cell therapy segment is attributed to the increasing number of products entering the market, the potential application of cell therapies in the treatment of autoimmune diseases, cancer, and infectious diseases, and the high number of ongoing clinical trials. More than 360 clinical trials focusing on CAR-T cell therapies and other cell-based therapies are being studied to interpret the potential of these therapies for treating various disease indications. Therefore, the demand for advanced therapy manufacturing services is anticipated to increase in the coming years.
A few of the major primary and secondary sources referred to while preparing the report on the US and Europe cell and gene therapy manufacturing services market are the Foundation for the National Institutes of Health, National Health Services, and Medicines and Healthcare Products Regulatory Agency.
An increase in number of approvals of cell and gene therapies and increasing popularity of outsourcing cell and gene therapy manufacturing services are among the major contributing factors influencing the growth of US and Europe cell and gene therapy manufacturing services market size. However, high initial cost of cell and gene therapy manufacturing services hinders the growth of the US and Europe cell and gene therapy manufacturing services market.
Cell and gene therapy (CGT) programs are rapidly advancing from research & development to clinical trials and commercial approval. Establishing a robust, repeatable, and sustainable process help to accelerate the development, avoiding manufacturing transfer-related delays. Additionally, cell and gene therapy comprises the next generation of life-enhancing and curative therapies. With therapies experiencing new approvals, the demand for skilled professionals in cell and gene therapy manufacturing services will rise.
Increasing Popularity of Outsourcing Cell and Gene Therapy Manufacturing
Cell and gene therapy manufacturing is a complex process, which makes the proper execution and overseeing of the operation crucial. Cell and gene therapy manufacturers have a limited number of qualified personnel who know biological and process engineering. Moreover, for experienced teams, managing the attempts to reach the first clinical trial using a manual, and open manufacturing method and then building a more commercially suitable process can be tricky. Therefore, these enterprises choose to work with contract development and manufacturing organizations (CDMOs) to accelerate their clinical studies and commercialization process. CDMOs provide product development, manufacturing, clinical trial support, and commercialization services to cell and gene therapy companies on a contract basis. Partnering with a CDMO enables scalability, speed to market, access to technical expertise without overhead costs, and cost efficiencies for cell and gene therapy manufacturers.
In January 2020, Deerfield Management Company and The Discovery Labs of MLP Ventures established the Center for Breakthrough Medicines in Pennsylvania, US. This new CDMO facility would occupy more than 40% of the campus created by The Discovery Labs. In that space, the CDMO would install 10 plasmid suites; 20 viral vector suites; 36 universal cell processing suites; and 20 current good manufacturing practice (cGMP) testing, process development, and cell banking suites. Deerfield Management Company and The Discovery Labs have invested US$ 1.1 billion to raise a technologically developed facility to support the manufacturing of cell and gene therapies. Further, in March 2020, Fujifilm Cellular Dynamics (FCDI) invested US$ 21 million in the cGMP-compliant production facility, which would be used for manufacturing FCDI’s pipeline of regenerative medicine therapies using induced pluripotent stem cells (iPSCs) and to provide CDMO services for production of iPSCs and iPSC-derived differentiated cells. In April 2022, ThermoGenesis established a CDMO facility in California, US to provide CDMO services to cell and gene therapy manufacturers, using its expertise in T-cell receptor (TCR), chimeric antigen receptor-T cell (CAR-T cell), tumor-infiltrating leukocyte (TIL), iPSC, natural killer cell (NK), and mesenchymal stem cell (MSC) manufacturing.
Outsourcing cell and gene therapy manufacturing to CDMOs proves cost-effective for manufacturers. Moreover, they gain access to the technologically advanced infrastructure and expertise of CDMOs. CDMOs employ proper, mapped processes for manufacturing cell and gene therapies. Thus, the increasing preference for outsourcing growing cell and gene therapy manufacturing to CDMOs fuels the US and Europe cell and gene therapy manufacturing services market growth.
Segmental Analysis
End User-Based Insights
Based on end user, the market is segmented into pharmaceutical and biotechnology companies and contract research organizations (CROs). The pharmaceutical and biotechnology companies segment held a larger share of the market in 2022 and the same segment is anticipated to register a higher CAGR in the market during the forecast period. Major US-based pharmaceutical and biotechnology companies committed to offering CGTs intended to treat acute and rare conditions, which are unresponsive to traditional approaches, include ElevateBio and Discovery Labs. These companies are focused on creating a completely new branch of pharmaceutical contract development and manufacturing organizations (CDMOs). They would compete with one another and with a handful of giant services firms by investing in CGTs. The aforementioned factors will be responsible for influential segmental growth thereby dominating the US and Europe cell and gene therapy manufacturing services market growth during 2022-2030.
Indication Insights
Based on indication, the US and Europe cell and gene therapy manufacturing services market is divided into cancer, orthopedics, and others. The cancer segment held the largest share of the market in 2022 and same segment is expected to grow at the highest CAGR during the forecast period.
Type Insights
Based on type, the cell and gene therapy manufacturing services market is segmented cell therapy and gene therapy. Cell therapy is segmented as autologous and allogenic. Further, gene therapy is bifurcated into viral vector and non-viral vector. Cell therapy helps treat disorders and diseases by restoring or changing certain groups of cells or providing cells to carry therapy through the body. Cell therapy forms or modifies cells outside the body before introducing into the patient. The cells may derive from the patient (autologous cells) or a donor (allogeneic cells). The growth of the cell therapy segment is attributed to the increasing number of products entering the market, the potential application of cell therapies in the treatment of autoimmune diseases, cancer, and infectious diseases, and the high number of ongoing clinical trials. More than 360 clinical trials focusing on CAR-T cell therapies and other cell-based therapies are being studied to interpret the potential of these therapies for treating various disease indications. Therefore, the demand for advanced therapy manufacturing services is anticipated to increase in the coming years.
A few of the major primary and secondary sources referred to while preparing the report on the US and Europe cell and gene therapy manufacturing services market are the Foundation for the National Institutes of Health, National Health Services, and Medicines and Healthcare Products Regulatory Agency.
1. INTRODUCTION
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 US and Europe Cell and Gene Therapy Manufacturing Services Market – by Type
1.3.2 US and Europe Cell and Gene Therapy Manufacturing Services Market – by Indication
1.3.3 US and Europe Cell and Gene Therapy Manufacturing Services Market – by Application
1.3.4 US and Europe Cell and Gene Therapy Manufacturing Services Market – by End User
1.3.5 US and Europe Cell and Gene Therapy Manufacturing Services Market – by Country & Region
2. US AND EUROPE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET – KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
3.2 Coverage
3.3 Secondary Research
3.4 Primary Research
4. US AND EUROPE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET – MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.2.1 US PEST Analysis
4.2.2 Europe PEST Analysis
4.3 Expert’s Opinion
5. US AND EUROPE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET – KEY MARKET DYNAMICS
5.1 Market Drivers
5.1.1 Increase in Number of Approval of Cell and Gene Therapies
5.1.2 Increasing Popularity of Outsourcing Cell and Gene Therapy Manufacturing
5.2 Market Restraints
5.2.1 High Cost of Cell and Gene Therapy Manufacturing
5.3 Market Opportunities
5.3.1 Strategic Initiatives by Companies
5.4 Future Trends
5.4.1 Automation of Cell and Gene Therapy Manufacturing Services
5.5 Impact Analysis
6. US AND EUROPE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET – COUNTRY & REGIONAL ANALYSIS
6.1 US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Forecast and Analysis
6.2 Market Positioning of Key Players
7. US AND EUROPE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET – REVENUE AND FORECAST TO 2030 – BY TYPE
7.1 Overview
7.2 US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
7.3 Cell Therapy
7.3.1 Overview
7.3.2 Cell Therapy: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
7.3.2.1 Autologous
7.3.2.1.1 Overview
7.3.2.1.2 Autologous: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
7.3.2.2 Allogenic
7.3.2.2.1 Overview
7.3.2.2.2 Allogenic: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Gene Therapy
7.4.1 Overview
7.4.2 Gene Therapy: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
7.4.2.1 Viral Vector
7.4.2.1.1 Overview
7.4.2.1.2 Viral Vector: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
7.4.2.2 Non-Viral Vector
7.4.2.2.1 Overview
7.4.2.2.2 Non-Viral Vector: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
8. US AND EUROPE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET ANALYSIS AND FORECASTS TO 2030 – BY INDICATION
8.1 Overview
8.2 US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
8.3 Cancer
8.3.1 Overview
8.3.2 Cancer: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Orthopedics
8.4.1 Overview
8.4.2 Orthopedics: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
9. US AND EUROPE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET – REVENUE AND FORECAST TO 2030 – BY APPLICATION
9.1 Overview
9.2 US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
9.4 Clinical Manufacturing
9.4.1 Overview
9.4.2 Clinical Manufacturing: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Commercial Manufacturing
9.5.1 Overview
9.5.2 Commercial Manufacturing: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
10. US AND EUROPE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET – REVENUE AND FORECAST TO 2030 – BY END USER
10.1 Overview
10.2 US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
10.4 Pharmaceutical and Biotechnology Companies
10.4.1 Overview
10.4.2 Pharmaceutical & Biotechnology Companies: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
10.5 Contract Research Organizations (CROs)
10.5.1 Overview
10.5.2 Contract Research Organizations (CROs): US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11. US AND EUROPE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET – REVENUE AND FORECAST TO 2030 – COUNTRY & REGIONAL ANALYSIS
11.1 US: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1 Overview
11.1.2 US: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.1.2.1 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020–2030 (US$ Million)
11.1.2.1.1 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020–2030 (US$ Million)
11.1.2.1.2 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020–2030 (US$ Million)
11.1.2.2 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020–2030 (US$ Million)
11.1.2.3 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020–2030 (US$ Million)
11.1.2.4 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020–2030 (US$ Million)
11.2 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market
11.2.1 Overview
11.2.2 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.3 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020–2030 (US$ Million)
11.2.3.1 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020–2030 (US$ Million)
11.2.3.2 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020–2030 (US$ Million)
11.2.4 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020–2030 (US$ Million)
11.2.5 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020–2030 (US$ Million)
11.2.6 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020–2030 (US$ Million)
11.2.7 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Country, 2022 & 2030 (%)
11.2.7.1 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.1.1 Overview
11.2.7.1.2 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.1.3 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020–2030 (US$ Million)
11.2.7.1.3.1 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020–2030 (US$ Million)
11.2.7.1.3.2 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020–2030 (US$ Million)
11.2.7.1.4 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020–2030 (US$ Million)
11.2.7.1.5 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020–2030 (US$ Million)
11.2.7.1.6 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020–2030 (US$ Million)
11.2.7.2 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.2.1 Overview
11.2.7.2.2 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.2.3 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020–2030 (US$ Million)
11.2.7.2.3.1 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020–2030 (US$ Million)
11.2.7.2.3.2 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020–2030 (US$ Million)
11.2.7.2.4 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020–2030 (US$ Million)
11.2.7.2.5 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020–2030 (US$ Million)
11.2.7.2.6 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020–2030 (US$ Million)
11.2.7.3 France: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.3.1 Overview
11.2.7.3.2 France: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.3.3 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020–2030 (US$ Million)
11.2.7.3.3.1 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020–2030 (US$ Million)
11.2.7.3.3.2 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020–2030 (US$ Million)
11.2.7.3.4 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020–2030 (US$ Million)
11.2.7.3.5 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020–2030 (US$ Million)
11.2.7.3.6 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020–2030 (US$ Million)
11.2.7.4 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.4.1 Overview
11.2.7.4.2 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.4.3 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020–2030 (US$ Million)
11.2.7.4.3.1 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020–2030 (US$ Million)
11.2.7.4.3.2 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020–2030 (US$ Million)
11.2.7.4.4 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020–2030 (US$ Million)
11.2.7.4.5 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020–2030 (US$ Million)
11.2.7.4.6 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020–2030 (US$ Million)
11.2.7.5 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.5.1 Overview
11.2.7.5.2 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.5.3 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020–2030 (US$ Million)
11.2.7.5.3.1 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020–2030 (US$ Million)
11.2.7.5.3.2 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020–2030 (US$ Million)
11.2.7.5.4 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020–2030 (US$ Million)
11.2.7.5.5 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020–2030 (US$ Million)
11.2.7.5.6 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020–2030 (US$ Million)
11.2.7.6 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.6.1 Overview
11.2.7.6.2 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.6.3 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020–2030 (US$ Million)
11.2.7.6.3.1 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020–2030 (US$ Million)
11.2.7.6.3.2 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020–2030 (US$ Million)
11.2.7.6.4 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020–2030 (US$ Million)
11.2.7.6.5 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020–2030 (US$ Million)
11.2.7.6.6 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020–2030 (US$ Million)
12. US AND EUROPE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET – INDUSTRY LANDSCAPE
12.1 Overview
12.2 Growth Strategies in US and Europe Cell and Gene Therapy Manufacturing Services Market
12.3 Organic Growth Strategies
12.3.1 Overview
12.4 Inorganic Growth Strategies
12.4.1 Overview
13. COMPANY PROFILES
13.1 Thermo Fisher Scientific Inc
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Merck KGaA
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Charles River Laboratories International Inc
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Lonza Group AG
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 WuXi AppTec Co Ltd?
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Catalent Inc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Takara Bio Inc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Nikon Corp
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 FUJIFILM Holdings Corp
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 National Resilience Inc
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
13.11 Oxford BioMedica Plc
13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments
14. APPENDIX
14.1 About The Insight Partners
14.2 Glossary of Terms
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 US and Europe Cell and Gene Therapy Manufacturing Services Market – by Type
1.3.2 US and Europe Cell and Gene Therapy Manufacturing Services Market – by Indication
1.3.3 US and Europe Cell and Gene Therapy Manufacturing Services Market – by Application
1.3.4 US and Europe Cell and Gene Therapy Manufacturing Services Market – by End User
1.3.5 US and Europe Cell and Gene Therapy Manufacturing Services Market – by Country & Region
2. US AND EUROPE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET – KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
3.2 Coverage
3.3 Secondary Research
3.4 Primary Research
4. US AND EUROPE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET – MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.2.1 US PEST Analysis
4.2.2 Europe PEST Analysis
4.3 Expert’s Opinion
5. US AND EUROPE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET – KEY MARKET DYNAMICS
5.1 Market Drivers
5.1.1 Increase in Number of Approval of Cell and Gene Therapies
5.1.2 Increasing Popularity of Outsourcing Cell and Gene Therapy Manufacturing
5.2 Market Restraints
5.2.1 High Cost of Cell and Gene Therapy Manufacturing
5.3 Market Opportunities
5.3.1 Strategic Initiatives by Companies
5.4 Future Trends
5.4.1 Automation of Cell and Gene Therapy Manufacturing Services
5.5 Impact Analysis
6. US AND EUROPE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET – COUNTRY & REGIONAL ANALYSIS
6.1 US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Forecast and Analysis
6.2 Market Positioning of Key Players
7. US AND EUROPE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET – REVENUE AND FORECAST TO 2030 – BY TYPE
7.1 Overview
7.2 US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
7.3 Cell Therapy
7.3.1 Overview
7.3.2 Cell Therapy: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
7.3.2.1 Autologous
7.3.2.1.1 Overview
7.3.2.1.2 Autologous: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
7.3.2.2 Allogenic
7.3.2.2.1 Overview
7.3.2.2.2 Allogenic: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Gene Therapy
7.4.1 Overview
7.4.2 Gene Therapy: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
7.4.2.1 Viral Vector
7.4.2.1.1 Overview
7.4.2.1.2 Viral Vector: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
7.4.2.2 Non-Viral Vector
7.4.2.2.1 Overview
7.4.2.2.2 Non-Viral Vector: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
8. US AND EUROPE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET ANALYSIS AND FORECASTS TO 2030 – BY INDICATION
8.1 Overview
8.2 US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
8.3 Cancer
8.3.1 Overview
8.3.2 Cancer: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Orthopedics
8.4.1 Overview
8.4.2 Orthopedics: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
9. US AND EUROPE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET – REVENUE AND FORECAST TO 2030 – BY APPLICATION
9.1 Overview
9.2 US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
9.4 Clinical Manufacturing
9.4.1 Overview
9.4.2 Clinical Manufacturing: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Commercial Manufacturing
9.5.1 Overview
9.5.2 Commercial Manufacturing: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
10. US AND EUROPE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET – REVENUE AND FORECAST TO 2030 – BY END USER
10.1 Overview
10.2 US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
10.4 Pharmaceutical and Biotechnology Companies
10.4.1 Overview
10.4.2 Pharmaceutical & Biotechnology Companies: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
10.5 Contract Research Organizations (CROs)
10.5.1 Overview
10.5.2 Contract Research Organizations (CROs): US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11. US AND EUROPE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET – REVENUE AND FORECAST TO 2030 – COUNTRY & REGIONAL ANALYSIS
11.1 US: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1 Overview
11.1.2 US: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.1.2.1 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020–2030 (US$ Million)
11.1.2.1.1 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020–2030 (US$ Million)
11.1.2.1.2 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020–2030 (US$ Million)
11.1.2.2 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020–2030 (US$ Million)
11.1.2.3 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020–2030 (US$ Million)
11.1.2.4 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020–2030 (US$ Million)
11.2 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market
11.2.1 Overview
11.2.2 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.3 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020–2030 (US$ Million)
11.2.3.1 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020–2030 (US$ Million)
11.2.3.2 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020–2030 (US$ Million)
11.2.4 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020–2030 (US$ Million)
11.2.5 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020–2030 (US$ Million)
11.2.6 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020–2030 (US$ Million)
11.2.7 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Country, 2022 & 2030 (%)
11.2.7.1 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.1.1 Overview
11.2.7.1.2 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.1.3 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020–2030 (US$ Million)
11.2.7.1.3.1 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020–2030 (US$ Million)
11.2.7.1.3.2 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020–2030 (US$ Million)
11.2.7.1.4 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020–2030 (US$ Million)
11.2.7.1.5 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020–2030 (US$ Million)
11.2.7.1.6 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020–2030 (US$ Million)
11.2.7.2 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.2.1 Overview
11.2.7.2.2 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.2.3 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020–2030 (US$ Million)
11.2.7.2.3.1 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020–2030 (US$ Million)
11.2.7.2.3.2 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020–2030 (US$ Million)
11.2.7.2.4 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020–2030 (US$ Million)
11.2.7.2.5 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020–2030 (US$ Million)
11.2.7.2.6 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020–2030 (US$ Million)
11.2.7.3 France: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.3.1 Overview
11.2.7.3.2 France: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.3.3 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020–2030 (US$ Million)
11.2.7.3.3.1 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020–2030 (US$ Million)
11.2.7.3.3.2 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020–2030 (US$ Million)
11.2.7.3.4 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020–2030 (US$ Million)
11.2.7.3.5 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020–2030 (US$ Million)
11.2.7.3.6 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020–2030 (US$ Million)
11.2.7.4 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.4.1 Overview
11.2.7.4.2 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.4.3 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020–2030 (US$ Million)
11.2.7.4.3.1 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020–2030 (US$ Million)
11.2.7.4.3.2 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020–2030 (US$ Million)
11.2.7.4.4 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020–2030 (US$ Million)
11.2.7.4.5 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020–2030 (US$ Million)
11.2.7.4.6 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020–2030 (US$ Million)
11.2.7.5 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.5.1 Overview
11.2.7.5.2 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.5.3 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020–2030 (US$ Million)
11.2.7.5.3.1 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020–2030 (US$ Million)
11.2.7.5.3.2 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020–2030 (US$ Million)
11.2.7.5.4 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020–2030 (US$ Million)
11.2.7.5.5 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020–2030 (US$ Million)
11.2.7.5.6 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020–2030 (US$ Million)
11.2.7.6 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.6.1 Overview
11.2.7.6.2 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
11.2.7.6.3 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020–2030 (US$ Million)
11.2.7.6.3.1 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020–2030 (US$ Million)
11.2.7.6.3.2 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020–2030 (US$ Million)
11.2.7.6.4 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020–2030 (US$ Million)
11.2.7.6.5 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020–2030 (US$ Million)
11.2.7.6.6 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020–2030 (US$ Million)
12. US AND EUROPE CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET – INDUSTRY LANDSCAPE
12.1 Overview
12.2 Growth Strategies in US and Europe Cell and Gene Therapy Manufacturing Services Market
12.3 Organic Growth Strategies
12.3.1 Overview
12.4 Inorganic Growth Strategies
12.4.1 Overview
13. COMPANY PROFILES
13.1 Thermo Fisher Scientific Inc
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Merck KGaA
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Charles River Laboratories International Inc
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Lonza Group AG
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 WuXi AppTec Co Ltd?
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Catalent Inc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Takara Bio Inc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Nikon Corp
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 FUJIFILM Holdings Corp
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 National Resilience Inc
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
13.11 Oxford BioMedica Plc
13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments
14. APPENDIX
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 2. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 3. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 4. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 5. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 6. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 7. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 8. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 9. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 10. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 11. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 12. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 13. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 14. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 15. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 16. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 17. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 18. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 19. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 20. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 21. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 22. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 23. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 24. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 25. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 26. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 27. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 28. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 29. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 30. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 31. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 32. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 33. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 34. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 35. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 36. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 37. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 38. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 39. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 40. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 41. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 42. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 43. Rest of Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 44. Rest of Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 45. Rest of Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 46. Rest of Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 47. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 48. Rest of Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 49. Recent Organic Growth Strategies in US and Europe Cell and Gene Therapy Manufacturing Services Market
Table 50. Recent Inorganic Growth Strategies in the US and Europe Cell and Gene Therapy Manufacturing Services Market
Table 51. Glossary of Terms
Table 1. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 2. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 3. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 4. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 5. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 6. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 7. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 8. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 9. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 10. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 11. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 12. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 13. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 14. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 15. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 16. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 17. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 18. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 19. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 20. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 21. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 22. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 23. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 24. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 25. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 26. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 27. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 28. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 29. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 30. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 31. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 32. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 33. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 34. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 35. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 36. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 37. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 38. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 39. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 40. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 41. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 42. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 43. Rest of Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 44. Rest of Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 45. Rest of Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 46. Rest of Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 47. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 48. Rest of Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 49. Recent Organic Growth Strategies in US and Europe Cell and Gene Therapy Manufacturing Services Market
Table 50. Recent Inorganic Growth Strategies in the US and Europe Cell and Gene Therapy Manufacturing Services Market
Table 51. Glossary of Terms
LIST OF FIGURES
Figure 1. US and Europe Cell and Gene Therapy Manufacturing Services Market Segmentation
Figure 2. US and Europe Cell and Gene Therapy Manufacturing Services Market, by Region
Figure 3. US and Europe Cell and Gene Therapy Manufacturing Services Market Overview
Figure 4. Cell Therapy Segment Held Largest Share of Type Segment in US and Europe Cell and Gene Therapy Manufacturing Services Market
Figure 5. US and Europe Cell and Gene Therapy Manufacturing Services Market, by Country & Region (US$ Million)
Figure 6. US and Europe Cell and Gene Therapy Manufacturing Services Market – Leading Country Markets (US$ Million)
Figure 7. US and Europe Cell and Gene Therapy Manufacturing Services Market – Industry Landscape
Figure 8. US: PEST Analysis
Figure 9. Europe: PEST Analysis
Figure 10. Experts’ Opinion
Figure 11. US and Europe Cell and Gene Therapy Manufacturing Services Market: Key Industry Dynamics
Figure 12. US and Europe Cell and Gene Therapy Manufacturing Services Market: Impact Analysis of Drivers and Restraints
Figure 13. US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue Forecast and Analysis – 2021-2030
Figure 14. Market Positioning of Key Players in US and Europe Cell and Gene Therapy Manufacturing Services Market
Figure 15. US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
Figure 16. Cell Therapy: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Autologous: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Allogenic: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Gene Therapy: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Viral Vector: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Non-Viral Vector: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application 2022 & 2030 (%)
Figure 23. Cancer: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Orthopedics: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Others: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 26. US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
Figure 27. Clinical Manufacturing: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28. Commercial Manufacturing: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 29. US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
Figure 30. Pharmaceutical & Biotechnology Companies: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 31. Contract Research Organizations (CROs): US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 32. United States: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Key Country – Revenue (2022) (US$ Million)
Figure 33. US: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 34. Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Key Country – Revenue (2022) (US$ Million)
Figure 35. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 36. Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Country, 2022 & 2030 (%)
Figure 37. Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 38. UK: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 39. France: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 40. Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 41. Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 42. Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 43. Growth Strategies in US and Europe Cell and Gene Therapy Manufacturing Services Market
Figure 1. US and Europe Cell and Gene Therapy Manufacturing Services Market Segmentation
Figure 2. US and Europe Cell and Gene Therapy Manufacturing Services Market, by Region
Figure 3. US and Europe Cell and Gene Therapy Manufacturing Services Market Overview
Figure 4. Cell Therapy Segment Held Largest Share of Type Segment in US and Europe Cell and Gene Therapy Manufacturing Services Market
Figure 5. US and Europe Cell and Gene Therapy Manufacturing Services Market, by Country & Region (US$ Million)
Figure 6. US and Europe Cell and Gene Therapy Manufacturing Services Market – Leading Country Markets (US$ Million)
Figure 7. US and Europe Cell and Gene Therapy Manufacturing Services Market – Industry Landscape
Figure 8. US: PEST Analysis
Figure 9. Europe: PEST Analysis
Figure 10. Experts’ Opinion
Figure 11. US and Europe Cell and Gene Therapy Manufacturing Services Market: Key Industry Dynamics
Figure 12. US and Europe Cell and Gene Therapy Manufacturing Services Market: Impact Analysis of Drivers and Restraints
Figure 13. US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue Forecast and Analysis – 2021-2030
Figure 14. Market Positioning of Key Players in US and Europe Cell and Gene Therapy Manufacturing Services Market
Figure 15. US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
Figure 16. Cell Therapy: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Autologous: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Allogenic: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Gene Therapy: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Viral Vector: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Non-Viral Vector: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application 2022 & 2030 (%)
Figure 23. Cancer: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Orthopedics: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Others: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 26. US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
Figure 27. Clinical Manufacturing: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28. Commercial Manufacturing: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 29. US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
Figure 30. Pharmaceutical & Biotechnology Companies: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 31. Contract Research Organizations (CROs): US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 32. United States: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Key Country – Revenue (2022) (US$ Million)
Figure 33. US: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 34. Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Key Country – Revenue (2022) (US$ Million)
Figure 35. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 36. Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Country, 2022 & 2030 (%)
Figure 37. Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 38. UK: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 39. France: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 40. Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 41. Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 42. Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 43. Growth Strategies in US and Europe Cell and Gene Therapy Manufacturing Services Market
